New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 16, 2012
06:02 EDTREGN, RHHBYRegeneron could benefit from bulk Avastin restriction, says Deutsche Bank
Deutsche Bank expects Congress to regulate compounding pharmacies more over time, which it feels could pressure demand for Roche's (RHHBY) Avastin since the drug for wet AMD is made in bulk at compounding pharmacies. Deutsche thinks branded wet AMD drug sales like Regeneron's (REGN) ylea could be a key beneficiary. The firm sees potential upside for Regeneron and keeps a Buy rating on the stock with a $190 price target.
News For REGN;RHHBY From The Last 14 Days
Check below for free stories on REGN;RHHBY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 30, 2014
12:33 EDTREGNRegeneron, Sanofi likely to file alirocumab BLA this year, says Piper Jaffray
Subscribe for More Information
12:27 EDTREGNOn The Fly: Midday Wrap
Subscribe for More Information
08:08 EDTREGNSanofi and Regeneron report positive Phase 2 results of alirocumab
Subscribe for More Information
July 29, 2014
18:38 EDTREGNRegeneron receives FDA approval for EYLEA for treatment of DME
Regeneron Pharmaceuticals announced that the FDA has approved EYLEA Injection for the treatment of Diabetic Macular Edema, or DME. The approval of EYLEA in DME was based on the one-year data from the phase 3 VISTA-DME and VIVID-DME studies of 862 patients. In Europe, the Committee for Medicinal Products for Human Use has given a positive opinion recommending approval for EYLEA in the treatment of DME. Regulatory submissions have also been made in Japan, Asia Pacific, and Latin America for the treatment of DME. In Japan, EYLEA has been additionally submitted for approval to regulators for the treatment of choroidal neovascularization secondary to pathologic myopia. A regulatory submission has been made in the U.S. and Europe for EYLEA for the treatment of Macular Edema following Branch Retinal Vein Occlusion.
09:09 EDTRHHBYRoche to hold an investor update
Subscribe for More Information
08:15 EDTRHHBYEnzo Biochem announces August 18 as date of Markman hearing in lawsuit
Subscribe for More Information
05:58 EDTRHHBYExelixis shares rallied on Roche rumors, says Piper Jaffray
Subscribe for More Information
July 28, 2014
07:30 EDTRHHBYQ1 Productions to hold a conference
Subscribe for More Information
July 25, 2014
07:35 EDTRHHBYEMA recommends new indication for RoActemra in severe arthritis
Subscribe for More Information
July 24, 2014
06:13 EDTRHHBYRoche reaffirms outlook for 2014
Subscribe for More Information
06:12 EDTRHHBYRoche reports 1H core EPS CHF 7.57 vs. CHF 7.58 last year
Subscribe for More Information
July 23, 2014
09:08 EDTRHHBYUltragenyx appoints Sunil Agarwal, M.D. as Chief Medical Officer
Subscribe for More Information
July 22, 2014
05:21 EDTRHHBYRoche announces Genentech Avastin granted priority review by FDA
Subscribe for More Information
July 21, 2014
10:02 EDTREGNOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Adeptus Health (ADPT) initiated with a Buy at Dougherty... Amphastar (AMPH) initiated with a Buy at Jefferies... Eclipse Resources (ECR) initiated with a Neutral at SunTrust... Fidelity National (FNF) initiated with a Buy at SunTrust... First American (FAF) initiated with a Buy at SunTrust... GoPro (GPRO) initiated with a Hold at Stifel... Imprivata (IMPR) initiated with an Outperform at Wells Fargo... Lifetime Brands (LCUT) initiated with a Buy at Sidoti... Materialise (MTLS) initiated with a Buy at BB&T... Regeneron (REGN) initiated with a Buy at Argus... STAG Industrial (STAG) initiated with a Buy at Sandler O'Neill... Signature Group (SGGH) initiated with a Buy at B. Riley... TCP International (TCPI) initiated with a Buy at Canaccord... Tessera (TSRA) initiated with a Buy at Craig-Hallum... Xunlei (XNET) initiated with a Perform at Oppenheimer.
07:42 EDTREGNRegeneron initiated with a Buy at Argus
Target $375.
07:11 EDTRHHBYInternational Society of DNA Vaccines to hold a conference
Subscribe for More Information
06:43 EDTRHHBYGrowing market for hepatitis-C treatment prompts legal scramble, WSJ says
Subscribe for More Information
July 20, 2014
15:42 EDTRHHBYRoche not looking for big acquisitions, Reuters says
Subscribe for More Information
July 18, 2014
06:10 EDTREGNRegeneron announces results from Phase 3 VIVID-DME trial of EYLEA
Subscribe for More Information
July 17, 2014
17:42 EDTRHHBYCepheid says Roche patent suit will not have material adverse impact on results
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use